PRT062607 HydrochlorideSYK inhibitor,potent and selective CAS# 1370261-97-4 |
- Piceatannol
Catalog No.:BCN5824
CAS No.:10083-24-6
- R788 disodium
Catalog No.:BCC3695
CAS No.:1025687-58-4
- GS-9973
Catalog No.:BCC5278
CAS No.:1229208-44-9
- R406 (free base)
Catalog No.:BCC2553
CAS No.:841290-80-0
- Fostamatinib (R788)
Catalog No.:BCC5082
CAS No.:901119-35-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1370261-97-4 | SDF | Download SDF |
| PubChem ID | 56948527 | Appearance | Powder |
| Formula | C19H24ClN9O | M.Wt | 429.91 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | P505-15 Hydrochloride | ||
| Solubility | H2O : ≥ 50 mg/mL (116.30 mM) DMSO : ≥ 33 mg/mL (76.76 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide;hydrochloride | ||
| SMILES | C1CCC(C(C1)N)NC2=NC=C(C(=N2)NC3=CC=CC(=C3)N4N=CC=N4)C(=O)N.Cl | ||
| Standard InChIKey | RMNLLPXCNDZJMJ-IDVLALEDSA-N | ||
| Standard InChI | InChI=1S/C19H23N9O.ClH/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28;/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27);1H/t15-,16+;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | PRT062607 (P505-15) HCl is a novel, highly selective inhibitor of Syk with IC50 of 1 nM, >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70. | |||||
| Targets | Syk | Fgr | MLK1 | |||
| IC50 | 1 nM | 81 nM | 88 nM | |||
| Cell experiment: [1] | |
| Cell lines | Primary B-cells, SU-DHL6 cells |
| Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
| Reacting condition | 1 μM, 24 hours |
| Applications | To compare the relative sensitivity of primary versus tumor B-cells, the mixing experiments in which SU-DHL6 was combined with human whole blood and treated with P505-15 were performed. Under these conditions, whereas the tumor B-cell line underwent apoptosis in response to SYK inhibition, primary B-cells did not. |
| Animal experiment: [1] | |
| Animal models | NOD/SCID mice injected with Ramos cells |
| Dosage form | Oral administration, 10, 15, or 20 mg/kg, twice daily |
| Application | A statistically significant reduction in average tumor weight was achieved in all dosing groups relative to vehicle control. It revealed that submicromolar concentrations of P505-15 prevented tumor formation by an aggressive NHL cell line in mice. |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: [1] Spurgeon S E, Coffey G, Fletcher L B, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. Journal of Pharmacology and Experimental Therapeutics, 2013, 344(2): 378-387. | |
PRT062607 Hydrochloride Dilution Calculator
PRT062607 Hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3261 mL | 11.6303 mL | 23.2607 mL | 46.5214 mL | 58.1517 mL |
| 5 mM | 0.4652 mL | 2.3261 mL | 4.6521 mL | 9.3043 mL | 11.6303 mL |
| 10 mM | 0.2326 mL | 1.163 mL | 2.3261 mL | 4.6521 mL | 5.8152 mL |
| 50 mM | 0.0465 mL | 0.2326 mL | 0.4652 mL | 0.9304 mL | 1.163 mL |
| 100 mM | 0.0233 mL | 0.1163 mL | 0.2326 mL | 0.4652 mL | 0.5815 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Abstract
PRT062607, a highly selective SYK inhibitor with therapeutic activity for B-cell malignancies, inhibited SYK-mediated BCR signaling, prevented BCR-mediated splenomegaly, suppressed NHL tumor growth and decreased cell viability in NHL and CLL. The combination of PRT062607 and fludarabine exhibited synergistic effects against primary CLL cells.
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PRT062607 Hydrochloride is a highly selective and novel SYK inhibitor with IC50 value of 1 nM. Spleen tyrosine kinase (SYK) is a cytoplasmic tyrosine kinase and primarily expressed in hematopoietic cells including B-cells.
PRT062607 Hydrochloride is an orally bioavailable SYK inhibitor and its affinity for SYK is at least 80-fold greater than other kinases. In NHL cell lines, PRT062607 Hydrochloride inhibits SYK activation and induces caspase dependent apoptosis. Also, PRT062607 Hydrochloride inhibited SYK and caused apoptosis of the tumor B-cell line [1].
PRT062607 Hydrochloride effectively antagonize CLL cell survival after BCR triggering. Moreover, they inhibit the secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell transfer toward beneath stromal cells, the tissue homing chemokines CXCL13 and CXCL12 [2].
In a mouse xenograft model, mice dosed with all three concentrations (twice daily with 10, 15, or 20 mg/kg) of PRT062607 Hydrochloride were protected from Ramos tumor growth [1].
References:
[1]. Spurgeon SE, Coffey G, Fletcher LB, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther, 2013, 344(2): 378-387.
[2]. Hoellenriegel J, Coffey GP, Sinha U, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia, 2012, 26(7): 1576-1583.
- 3',4'-Di-O-acetyl-2',6'-di-O-p-coumaroylastragalin
Catalog No.:BCN6610
CAS No.:137018-33-8
- Amprolium HCl
Catalog No.:BCC4626
CAS No.:137-88-2
- L-Ascorbyl 6-palmitate
Catalog No.:BCC4915
CAS No.:137-66-6
- Lidocaine
Catalog No.:BCC1084
CAS No.:137-58-6
- Calcium pantothenate
Catalog No.:BCN8503
CAS No.:137-08-6
- Sophoraflavanone I
Catalog No.:BCN6863
CAS No.:136997-69-8
- Sophoraflavanone H
Catalog No.:BCN6864
CAS No.:136997-68-7
- (-)-Syringaresnol-4-O-beta-D-apiofuranosyl-(1->2)-beta-D-glucopyranoside
Catalog No.:BCN1578
CAS No.:136997-64-3
- AHU-377 hemicalcium salt
Catalog No.:BCC5141
CAS No.:1369773-39-6
- Macranthoidin B
Catalog No.:BCN5938
CAS No.:136849-88-2
- TOTU
Catalog No.:BCC2826
CAS No.:136849-72-4
- 1-Dehydro-10-gingerdione
Catalog No.:BCN3338
CAS No.:136826-50-1
- Pseudoginsenoside Rh2
Catalog No.:BCC8353
CAS No.:1370264-16-6
- Episyringaresinol 4'-O-β-D-glncopyranoside
Catalog No.:BCC8957
CAS No.:137038-13-2
- Walsuralactam A
Catalog No.:BCN6734
CAS No.:1370556-82-3
- PACAP 1-38
Catalog No.:BCC6962
CAS No.:137061-48-4
- Alprenolol hydrochloride
Catalog No.:BCC7490
CAS No.:13707-88-5
- Pimecrolimus
Catalog No.:BCC4703
CAS No.:137071-32-0
- Tolfenamic Acid
Catalog No.:BCC4438
CAS No.:13710-19-5
- (±)-Marmesin
Catalog No.:BCN3618
CAS No.:13710-70-8
- BETP
Catalog No.:BCC6286
CAS No.:1371569-69-5
- Toddalosin
Catalog No.:BCN6194
CAS No.:137182-37-7
- Spinorphin
Catalog No.:BCC2349
CAS No.:137201-62-8
- Sodium Orthovanadate
Catalog No.:BCC3856
CAS No.:13721-39-6
